» Articles » PMID: 23338234

Temporal Dynamics of the Primary Human T Cell Response to Yellow Fever Virus 17D As It Matures from an Effector- to a Memory-type Response

Overview
Journal J Immunol
Date 2013 Jan 23
PMID 23338234
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

The live attenuated yellow fever virus (YFV) 17D vaccine provides a good model to study immune responses to an acute viral infection in humans. We studied the temporal dynamics, composition, and character of the primary human T cell response to YFV. The acute YFV-specific effector CD8 T cell response was broad and complex; it was composed of dominant responses that persisted into the memory population, as well as of transient subdominant responses that were not detected at the memory stage. Furthermore, HLA-A2- and HLA-B7-restricted YFV epitope-specific effector cells predominantly displayed a CD45RA(-)CCR7(-)PD-1(+)CD27(high) phenotype, which transitioned into a CD45RA(+)CCR7(-)PD-1(-)CD27(low) memory population phenotype. The functional profile of the YFV-specific CD8 T cell response changed in composition as it matured from an effector- to a memory-type response, and it tended to become less polyfunctional during the course of this transition. Interestingly, activation of CD4 T cells, as well as FOXP3(+) T regulatory cells, in response to YFV vaccination preceded the kinetics of the CD8 T cell response. The present results contribute to our understanding of how immunodominance patterns develop, as well as the phenotypic and functional characteristics of the primary human T cell response to a viral infection as it evolves and matures into memory.

Citing Articles

Balancing functions of regulatory T cells in mosquito-borne viral infections.

Sann S, Kleinewietfeld M, Cantaert T Emerg Microbes Infect. 2024; 13(1):2304061.

PMID: 38192073 PMC: 10812859. DOI: 10.1080/22221751.2024.2304061.


Human circulating and tissue-resident memory CD8 T cells.

Buggert M, Price D, Mackay L, Betts M Nat Immunol. 2023; 24(7):1076-1086.

PMID: 37349380 DOI: 10.1038/s41590-023-01538-6.


Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.

Sandberg J, Lofling M, Varnaite R, Emgard J, Al-Tawil N, Lindquist L PLoS Negl Trop Dis. 2023; 17(2):e0010616.

PMID: 36758067 PMC: 9946270. DOI: 10.1371/journal.pntd.0010616.


Evaluation of Two Adjuvant Formulations for an Inactivated Yellow Fever 17DD Vaccine Candidate in Mice.

Cajaraville A, Gomes M, Azamor T, Pereira R, Neves P, De Luca P Vaccines (Basel). 2023; 11(1).

PMID: 36679918 PMC: 9865672. DOI: 10.3390/vaccines11010073.


and arboviral MHC class I-restricted-epitope signatures reveal immunodominance and poor overlapping patterns.

Lopes-Ribeiro A, Araujo F, Oliveira P, Teixeira L, Ferreira G, Lourenco A Front Immunol. 2022; 13:1035515.

PMID: 36466864 PMC: 9713826. DOI: 10.3389/fimmu.2022.1035515.